Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)

20260 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier, NCT06868212.

Good health and well-being

Published in: Dermatology and Therapy

Field-Weighted Citation Impact: 0.00